【RevoMic】Q2 FY2024 Financial Results｜Revenue Unknown (YoY Unknown)

Performance Overview

RevoMic received 23.9 million yen (including tax) in FY2025 from a government grant related to the NEDO's cyber-physical development project utilizing quantum and classical hybrid technology, with the total support amount reaching 58.5 million yen (including tax). This support facilitates the development of foundational technology for drug discovery research leveraging quantum and AI technologies, including patent applications and academic paper preparations. In the fiscal midterm ending in March 2027, grant income is scheduled to be recognized as non-operating income, and this has been incorporated into the full-year earnings forecast announced in May 2026.

Future Outlook and Corporate Activities

Going forward, it is expected that the grant income will be recorded as non-operating income in the FY2027 midterm, with continued strengthening of research and development in quantum and AI technologies. The insights gained are highly compatible with aptamer-based drug discovery research and are expected to contribute to more advanced R&D. Financially, the confirmed grants and increasing cumulative support amount are strengthening the foundation for ongoing research activities.